OpGen

OpGen Days Payable Outstanding

The Days Payable Outstanding (DPO) of OpGen (OPGN) as of Oct 24, 2026 is 130.76. In the previous year, Days Payable Outstanding (DPO) was 2,694.79 — a change of -95.15% (lower).

Days Payable Outstanding

130.76

YoY

-95.15%

Last updated:

Days Payable Outstanding (DPO) of OpGen is 2025 130.76 . Days Payable Outstanding (DPO) of OpGen was 2024 2,694.79 . It decreases by -95.15% lower compared to the previous year.

The OpGen Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
320.71 USD
Jan 1, 2019
236.18 USD
Jan 1, 2020
177.25 USD
Jan 1, 2021
167.52 USD
Jan 1, 2022
44.86 USD
Jan 1, 2023
11.56 USD
Jan 1, 2024
2,694.79 USD
Jan 1, 2025
130.76 USD
The OpGen Days Payable Outstanding history
YEARDays Payable OutstandingYoY
130.76-95.15%
2,694.79+23,208.23%
11.56-74.23%
44.86-73.22%
167.52-5.49%
177.25-24.95%
236.18-26.36%
320.71+10.79%
289.46-18.66%
355.86-33.97%
538.96+21.14%
444.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Days Payable Outstanding (DPO) of OpGen is 130.76 in 2025.

Days Payable Outstanding (DPO) of OpGen changed from 2,694.79 to 130.76, representing a -95.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) OpGen since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OpGen

All Key Metrics — OpGen